Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

Kurt Ullman  |  June 15, 2017

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a…

U.S. State Attorneys General Probe Opioid Drug Companies

Nate Raymond  |  June 15, 2017

(Reuters)—A bipartisan group of state attorneys general announced on Thursday that they are jointly investigating the marketing and sales practices of drug companies that manufacture opioid painkillers at the center of a national addiction epidemic. Attorneys general from states including Massachusetts, Texas, Illinois and Pennsylvania announced the investigation two weeks after Ohio Attorney General Mike…

Rheumatology Online Educational Courses Among Key ARHP Pillars

Paul M. Adam, MSW, & Afton L. Hassett, PsyD  |  June 15, 2017

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. The ARHP Online Education Portfolio continues to evolve and grow. The Advanced Rheumatology Course (ARC) and the Fundamentals of Rheumatology Course (FRC)…

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD  |  June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

Rheumatologists Treating Patients with HIV Face Treatment, Diagnostic Challenges

Ruth Jessen Hickman, MD  |  June 15, 2017

Rheumatologists treating HIV patients in 2017 must think through many important factors as this population ages. As we continue to learn, rheumatologists must consider important drug–drug interactions, relatively uncommon rheumatological presentations of HIV, as well as specific diagnostic challenges. Working closely with infectious disease specialists is the best way to achieve optimum care for this…

RISE Summit Establishes Priorities, Direction for Registry

Kelly Tyrrell  |  June 15, 2017

On Feb. 16, ACR leaders, insurers, pharmaceutical representatives, patients, patient advocacy representatives and more met in Scottsdale, Ariz. They came together for the first annual RISE Summit, aimed at setting strategic priorities and goals for the Rheumatology Informatics System for Effectiveness (RISE) Registry, the qualified clinical data registry developed by the ACR. The Rise of…

ACR Works for Global Access to Meeting

Susan Bernstein  |  June 15, 2017

Thousands of attendees travel to the ACR/ARHP Annual Meeting from outside the U.S. to learn, network and exchange ideas. From Nov. 3–8 in San Diego, speakers from more than 30 different countries are scheduled to participate. The ACR is taking action to maintain diverse attendance in a challenging climate for international travel. New traveler vetting and…

The ACR Is Exploring a Rheumatology-Specific APM

Mary Beth Nierengarten  |  June 15, 2017

In response to the required changes in reimbursement from fee for service to value-based payment under the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015, the ACR is exploring development of a rheumatology-specific alternative payment model (APM) for rheumatologists and practices, which would provide an additional option for payment other than the Merit-Based Incentive…

Texas Rheumatologists Push for Passage of Step Therapy Reforms

Gretchen Henkel  |  June 15, 2017

On May 25, with Gov. Greg Abbott’s signing of Senate Bill 680, Texas became the fourth state this year to increase protection for patients subject to insurers’ step therapy protocols. The State of Texas Association of Rheumatologists (STAR) joined with 35 other professional societies and patient advocacy organizations in urging passage of S.B. 680. The…

More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

Susan Bernstein  |  June 14, 2017

Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

  • « Previous Page
  • 1
  • …
  • 419
  • 420
  • 421
  • 422
  • 423
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences